Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01199146 · ClinicalTrials.gov registry record · Phase 2
Abiraterone Post Ketoconazole for Prostate Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01199146 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 42 participants.
The verdict
NCT01199146, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a phase II, open label, single center study to evaluate the efficacy of abiraterone acetate (CB7630) administered to patients with castrate resistant prostate cancer who have experienced disease progression on ketoconazole. It is hypothesized that abiraterone will be active in patients who have experienced disease progression on ketoconazole
Interventions
- DRUG Abiraterone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2010-09-10 |
| Est. Completion | 2016-03-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01199146
The ClinicalTrials.gov registry entry for NCT01199146 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abiraterone acetate is the first listed.
NCT01199146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01199146 about?
NCT01199146 is a clinical study titled "Abiraterone Post Ketoconazole for Prostate Cancer". This is a phase II, open label, single center study to evaluate the efficacy of abiraterone acetate (CB7630) administered to patients with castrate resistant prostate cancer who have experienced disease progression on ketoconazole. It is hypothesized that abiraterone will be active in patients who ...
What is the current status of trial NCT01199146?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2010-09-10. Estimated completion is 2016-03-14.
What interventions are being tested in trial NCT01199146?
The interventions under investigation include: Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT01199146?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.